{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T23:11:56Z","timestamp":1782601916162,"version":"3.54.5"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2013,11,12]],"date-time":"2013-11-12T00:00:00Z","timestamp":1384214400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1007\/s11255-013-0596-7","type":"journal-article","created":{"date-parts":[[2013,11,11]],"date-time":"2013-11-11T13:48:31Z","timestamp":1384177711000},"page":"1019-1024","source":"Crossref","is-referenced-by-count":10,"title":["What is the impact of immunosuppressive treatment on the post-transplant renal osteopathy?"],"prefix":"10.1007","volume":"46","author":[{"given":"Kristina","family":"Blaslov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lea","family":"Katalinic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petar","family":"Kes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Goce","family":"Spasovski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruzica","family":"Smalcelj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolina","family":"Basic-Jukic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,11,12]]},"reference":[{"key":"596_CR1","first-page":"S1","volume":"113","author":"Kidney Disease","year":"2009","unstructured":"Disease Kidney (2009) Improving Global Outcomes (KDIGO) CKD-MBD Work Group. Kidney Int Suppl 113:S1\u2013S130","journal-title":"Kidney Int Suppl"},{"key":"596_CR2","first-page":"2096","volume":"10","author":"WH Grotz","year":"1995","unstructured":"Grotz WH, Mundinger FA, Rasenack J et al (1995) Bone loss after kidney transplantation (A longitudinal study in 115 graft recipients). Nephrol Dial Transplant 10:2096","journal-title":"Nephrol Dial Transplant"},{"key":"596_CR3","first-page":"1764","volume":"26","author":"U Nisbeth","year":"1994","unstructured":"Nisbeth U, Lindh E, Ljunghall S et al (1994) Fracture frequency after kidney transplantation. Transplant Proc 26:1764","journal-title":"Transplant Proc"},{"key":"596_CR4","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/j.1432-2277.2008.00665.x","volume":"21","author":"C Mitterbauer","year":"2008","unstructured":"Mitterbauer C, Oberbauer R (2008) Bone disease after kidney transplantation. Transplant Int 21:615\u2013624","journal-title":"Transplant Int"},{"key":"596_CR5","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.transproceed.2010.03.069","volume":"42","author":"A Sessa","year":"2010","unstructured":"Sessa A, Esposito GD, Iavicoli E et al (2010) Immunosuppressive agents and bone disease in renal transplant patients with hypercalcemia. Transplant Proc 42:1148\u20131155","journal-title":"Transplant Proc"},{"key":"596_CR6","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1097\/00007890-200208150-00012","volume":"74","author":"EA O\u2019Shaughnessy","year":"2002","unstructured":"O\u2019Shaughnessy EA, Dahl DC, Smith CL, Kasiske BL (2002) Risk factors for fractures in kidney transplantation. Transplantation 74:362\u2013366","journal-title":"Transplantation"},{"issue":"1","key":"596_CR7","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.transproceed.2007.11.040","volume":"40","author":"G Bozkaya","year":"2008","unstructured":"Bozkaya G, Nart A, Uslu A, Onman T, Aykas A, Do\u011fan M, Karaca B (2008) Impact of calcineurin inhibitors on bone metabolism in primary kidney transplant patients. Transplant Proc 40(1):151\u2013155","journal-title":"Transplant Proc"},{"key":"596_CR8","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1359\/jbmr.2001.16.10.1863","volume":"16","author":"S Patel","year":"2001","unstructured":"Patel S, Kwan JTC, McCloskey E et al (2001) Prevalence and causes of low bone density and fractures in kidney transplant patients. J Bone Miner Res 16:1863\u20131870","journal-title":"J Bone Miner Res"},{"issue":"12","key":"596_CR9","doi-asserted-by":"crossref","first-page":"3823","DOI":"10.1093\/ndt\/gfq513","volume":"25","author":"Endorsement of the Kidney Disease Improving Global Outcomes","year":"2010","unstructured":"Endorsement of the Kidney Disease Improving Global Outcomes (2010) (KDIGO) chronic kidney disease-mineral and bone disorder (CKD-MBD) Guidelines: a European renal best practice (ERBP) commentary statement. Nephrol Dial Transplant 25(12):3823\u20133831","journal-title":"Nephrol Dial Transplant"},{"key":"596_CR10","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/j.1399-0012.1995.tb00291.x","volume":"9","author":"HD McIntyre","year":"1995","unstructured":"McIntyre HD, Menzies B, Rigby R et al (1995) Long-term bone loss after renal transplantation: comparison of immunosuppressive regimens. Clin Transplant 9:20\u201324","journal-title":"Clin Transplant"},{"issue":"3","key":"596_CR11","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/01.TP.0000043926.74349.6D","volume":"75","author":"JG Heaf","year":"2003","unstructured":"Heaf JG (2003) Bone disease after renal transplantation. Transplantation 75(3):315\u2013325","journal-title":"Transplantation"},{"issue":"6","key":"596_CR12","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.2215\/CJN.01510506","volume":"1","author":"JR Weisinger","year":"2006","unstructured":"Weisinger JR, Carlini RG, Rojas E, Bellorin-Font E (2006) Bone disease after renal transplantation. CJASN 1(6):1300\u20131313","journal-title":"CJASN"},{"issue":"Suppl 2","key":"596_CR13","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1365-2362.2006.01661.x","volume":"36","author":"A Ferreira","year":"2006","unstructured":"Ferreira A (2006) Development of renal bone disease. Eur J Clin Invest 36(Suppl 2):2\u201312","journal-title":"Eur J Clin Invest"},{"key":"596_CR14","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1093\/ndt\/gfh128","volume":"19","author":"P Evenepoel","year":"2004","unstructured":"Evenepoel P, Claes K, Kuypers D et al (2004) Natural history of parathyroid function and calcium metabolism after kidney transplantation: a single-centre study. Nephrol Dial Transplant 19:1281\u20131287","journal-title":"Nephrol Dial Transplant"},{"key":"596_CR15","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1046\/j.1523-1755.2003.00938.x","volume":"63","author":"E Rojas","year":"2003","unstructured":"Rojas E, Carlini RG, Clesca P et al (2003) The pathogenesis of osteodystrophy after renal transplantation as detected by early alterations in bone remodeling. Kidney Int 63:1915\u20131923","journal-title":"Kidney Int"},{"issue":"5","key":"596_CR16","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/j.transproceed.2006.02.077","volume":"38","author":"SD Navaneethan","year":"2006","unstructured":"Navaneethan SD, Sankarasubbaiyan S, Gross MD, Jeevanantham V, Monk RD (2006) Tacrolimus-associated hypomagnesemia in renal transplant recipients. Transplant Proc 38(5):1320\u20131322","journal-title":"Transplant Proc"},{"key":"596_CR17","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1080\/07315724.2009.10719764","volume":"28","author":"RK Rude","year":"2009","unstructured":"Rude RK, Singer FR, Gruber HE (2009) Skeletal and hormonal effects of magnesium deficiency. J Am Coll Nutr 28:131\u2013141","journal-title":"J Am Coll Nutr"},{"key":"596_CR18","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s11914-009-0020-5","volume":"7","author":"KL Tucker","year":"2009","unstructured":"Tucker KL (2009) Osteoporosis prevention and nutrition. Curr Osteoporos Rep 7:111\u2013117","journal-title":"Curr Osteoporos Rep"},{"key":"596_CR19","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1177\/147323000703500514","volume":"35","author":"M Mutlu","year":"2007","unstructured":"Mutlu M, Argun M, Kilic E, Saraymen R, Yazar S (2007) Magnesium, zinc and copper status in osteoporotic, osteopenic and normal post-menopausal women. J Int Med Res 35:692\u2013695","journal-title":"J Int Med Res"},{"key":"596_CR20","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1097\/01.TP.0000149698.79739.EF","volume":"79","author":"J Cunningham","year":"2005","unstructured":"Cunningham J (2005) Posttransplantation bone disease. Transplantation 79:629\u2013634","journal-title":"Transplantation"},{"issue":"1","key":"596_CR21","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s11255-007-9310-y","volume":"40","author":"H Sadideen","year":"2008","unstructured":"Sadideen H, Covic A, Goldsmith D (2008) Mineral and bone disorder after renal transplantation: a review. Int Urol Nephrol 40(1):171\u2013184","journal-title":"Int Urol Nephrol"},{"key":"596_CR22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jbmr.5650110102","volume":"11","author":"S Epstein","year":"1996","unstructured":"Epstein S (1996) Post-transplantation bone disease: the role of immunosuppressive agents and the skeleton. J Bone Miner Res 11:1\u20137","journal-title":"J Bone Miner Res"},{"key":"596_CR23","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1007\/BF02556041","volume":"45","author":"PJ Stewart","year":"1989","unstructured":"Stewart PJ, Stern PH (1989) Cyclosporines: correlation of immunosuppressive activity and inhibition of bone resorption. Calcif Tissue Int 45:222\u2013226","journal-title":"Calcif Tissue Int"},{"key":"596_CR24","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1055\/s-2007-1009189","volume":"21","author":"PJ Stewart","year":"1989","unstructured":"Stewart PJ, Stern PH (1989) Interaction of cyclosporine A and calcitonin on bone resorption in vitro. Horm Metab Res 21:194\u2013197","journal-title":"Horm Metab Res"},{"key":"596_CR25","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1006\/bbrc.1998.9785","volume":"254","author":"EM Awumey","year":"1999","unstructured":"Awumey EM, Moonga BS, Sodam BR et al (1999) Molecular and functional evidence for calcineurin-A alpha and beta isoforms in the osteoclast: novel insights into cyclosporin A action on bone resorption. Biochem Biophys Res Commun 254:248\u2013252","journal-title":"Biochem Biophys Res Commun"},{"key":"596_CR26","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1210\/endo.137.6.8641176","volume":"137","author":"FJ Buchinsky","year":"1996","unstructured":"Buchinsky FJ, Ma Y, Mann GN et al (1996) T lymphocytes play a critical role in the development of cyclosporin A-induced osteopenia. Endocrinology 137:2278\u20132285","journal-title":"Endocrinology"},{"key":"596_CR27","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/S0140-6736(00)04765-6","volume":"357","author":"C Ponticelli","year":"2001","unstructured":"Ponticelli C, Aroldi A (2001) Osteoporosis after organ transplantation. Lancet 357:1623\u20131624","journal-title":"Lancet"},{"key":"596_CR28","first-page":"2652","volume":"26","author":"W Grotz","year":"1994","unstructured":"Grotz W, Mundinger A, Gugel B et al (1994) Missing impact of cyclosporine on osteoporosis in renal transplant recipients. Transplant Proc 26:2652\u20132653","journal-title":"Transplant Proc"},{"key":"596_CR29","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/BF02678145","volume":"68","author":"A Monegal","year":"2001","unstructured":"Monegal A, Navasa M, Guanabens N et al (2001) Bone mass and mineral metabolism in liver transplant patients treated with FK506 or cyclosporine A. Calcif Tissue Int 68:83\u201386","journal-title":"Calcif Tissue Int"},{"issue":"1","key":"596_CR30","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1159\/000328874","volume":"34","author":"CT Lee","year":"2011","unstructured":"Lee CT, Ng HY, Lien YH, Lai LW, Wu MS, Lin CR, Chen HC (2011) Effects of cyclosporine, tacrolimus and rapamycin on renal calcium transport and vitamin D metabolism. Am J Nephrol 34(1):87\u201394","journal-title":"Am J Nephrol"},{"issue":"5","key":"596_CR31","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.molcel.2010.05.017","volume":"38","author":"CK Yip","year":"2010","unstructured":"Yip CK, Murata K, Walz T, Sabatini DM, Kang SA (2010) Structure of the human mTOR complex I and its implications for rapamycin inhibition. Mol Cell 38(5):768\u2013774","journal-title":"Mol Cell"},{"key":"596_CR32","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ccr.2007.05.008","volume":"12","author":"DA Guertin","year":"2007","unstructured":"Guertin DA, Sabatini DM (2007) Defining the role of mTOR in cancer. Cancer Cell 12:9\u201322","journal-title":"Cancer Cell"},{"key":"596_CR33","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0092-8674(02)00833-4","volume":"110","author":"K Hara","year":"2002","unstructured":"Hara K, Maruki Y, Long X, Yoshino K, Oshiro N, Hidayat S, Tokunaga C, Avruch J, Yonezawa K (2002) Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell 110:177\u2013189","journal-title":"Cell"},{"key":"596_CR34","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1083\/jcb.200408161","volume":"167","author":"BD Manning","year":"2004","unstructured":"Manning BD (2004) Balancing Akt with S6\u00a0K: implications for both metabolic diseases and tumorigenesis. J Cell Biol 167:399\u2013403","journal-title":"J Cell Biol"},{"key":"596_CR35","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.cell.2009.03.046","volume":"137","author":"TR Peterson","year":"2009","unstructured":"Peterson TR, Laplante M, Thoreen CC, Sancak Y, Kang SA, Kuehl WM, Gray NS, Sabatini DM (2009) DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell 137:873\u2013886","journal-title":"Cell"},{"key":"596_CR36","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMra055323","volume":"355","author":"PB Crino","year":"2006","unstructured":"Crino PB, Nathanson KL, Henske EP (2006) The tuberous sclerosis complex. N Engl J Med 355:1345\u20131356","journal-title":"N Engl J Med"},{"issue":"1","key":"596_CR37","first-page":"27","volume":"31","author":"D Hernandez","year":"2011","unstructured":"Hernandez D, Martinez D, Gutierrez E et al (2011) Clinical evidence on the use of anti-mTOR drugs in renal transplantation. Nefrologia 31(1):27\u201334","journal-title":"Nefrologia"},{"key":"596_CR38","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/00007890-200101270-00019","volume":"71","author":"AS MacDonald","year":"2001","unstructured":"MacDonald AS (2001) A worldwide, phase III, randomised, controlled, safety and efficacy study of sirolimus\/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. The Rapamune Global Study Group. Transplantation 71:271\u2013280","journal-title":"Transplantation"},{"issue":"2","key":"596_CR39","doi-asserted-by":"crossref","first-page":"153","DOI":"10.2165\/00002018-200528020-00006","volume":"28","author":"DR Kuypers","year":"2005","unstructured":"Kuypers DR (2005) Benefit-risk assessment of sirolimus in renal transplantation. Drug Saf 28(2):153\u2013181","journal-title":"Drug Saf"},{"issue":"1","key":"596_CR40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1399-0012.2007.00739.x","volume":"22","author":"SM Flechner","year":"2008","unstructured":"Flechner SM, Kobashigawa J, Klintmalm G (2008) Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity. Clin Transplant 22(1):1\u201315","journal-title":"Clin Transplant"},{"issue":"1","key":"596_CR41","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/00007890-199707150-00008","volume":"64","author":"W Schuler","year":"1997","unstructured":"Schuler W, Sedrani R, Cottens S et al (1997) SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. Transplantation 64(1):36\u201342","journal-title":"Transplantation"},{"issue":"10","key":"596_CR42","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1111\/j.1600-6143.2005.01063.x","volume":"5","author":"S V\u00edtko","year":"2005","unstructured":"V\u00edtko S, Margreiter R, Weimar W et al (2005) Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients. Am J Transplant 5(10):2521\u20132530","journal-title":"Am J Transplant"},{"issue":"2","key":"596_CR43","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/01.TP.0000164352.65613.24","volume":"80","author":"MI Lorber","year":"2005","unstructured":"Lorber MI, Mulgaonkar S, Butt KM et al (2005) Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: a 3-year randomized, multicenter, phase III study. Transplantation 80(2):244\u2013252","journal-title":"Transplantation"},{"issue":"3","key":"596_CR44","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.transproceed.2006.12.026","volume":"39","author":"J Morales","year":"2007","unstructured":"Morales J, Fierro A, Benavente D et al (2007) Conversion from a calcineurin inhibitor-based immunosuppressive regimen to everolimus in renal transplant recipients: effect on renal function and proteinuria. Transplant Proc 39(3):591\u2013593","journal-title":"Transplant Proc"},{"issue":"2","key":"596_CR45","first-page":"133","volume":"23","author":"L Rostaing","year":"2010","unstructured":"Rostaing L, Kamar N (2010) mTOR inhibitor\/proliferation signal inhibitors: entering or leaving the field? J Nephrol 23(2):133\u2013142","journal-title":"J Nephrol"},{"key":"596_CR46","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1007\/s00467-007-0456-8","volume":"22","author":"O Alvarez-Garcia","year":"2007","unstructured":"Alvarez-Garcia O, Carbajo-Pe\u2032rez E, Garcia E et al (2007) Rapamycin retards growth and causes marked alterations in the growth plate of young rats. Pediatr Nephrol 22:954\u2013961","journal-title":"Pediatr Nephrol"},{"issue":"5","key":"596_CR47","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1038\/bjp.2008.167","volume":"154","author":"JH Holstein","year":"2008","unstructured":"Holstein JH, Klein M, Garcia P (2008) Rapamycin affects early fracture healing in mice. Br J Pharmacol 154(5):1055\u20131062","journal-title":"Br J Pharmacol"},{"key":"596_CR48","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1101\/gad.1212704","volume":"18","author":"N Hay","year":"2004","unstructured":"Hay N, Sonenberg N (2004) Upstream and downstream of mTOR. Genes Dev 18:1926\u20131945","journal-title":"Genes Dev"},{"key":"596_CR49","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/ki.2010.173","volume":"78","author":"O Alvarez-Garcia","year":"2010","unstructured":"Alvarez-Garcia O, Garcia-Lopez E, Lored V (2010) Rapamycin induces growth retardation by disrupting angiogenesis in the growth plate. Kidney Int 78:561\u2013568","journal-title":"Kidney Int"},{"issue":"5","key":"596_CR50","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1016\/j.bone.2004.07.013","volume":"35","author":"M Kneissel","year":"2004","unstructured":"Kneissel M, Luong-Nguyen NH, Baptist M (2004) Everolimus suppresses cancellous bone loss, bone resorption, and cathepsin K expression by osteoclasts. Bone 35(5):1144\u20131156","journal-title":"Bone"},{"issue":"9","key":"596_CR51","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1111\/j.1432-2277.2005.00163.x","volume":"18","author":"JM Campistol","year":"2005","unstructured":"Campistol JM, Holt DW, Epstein S (2005) Bone metabolism in renal transplant patients treated with cyclosporine or sirolimus. Transplant Int 18(9):1028\u20131035","journal-title":"Transplant Int"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-013-0596-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11255-013-0596-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-013-0596-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T20:09:43Z","timestamp":1746043783000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11255-013-0596-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11,12]]},"references-count":51,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["596"],"URL":"https:\/\/doi.org\/10.1007\/s11255-013-0596-7","relation":{},"ISSN":["0301-1623","1573-2584"],"issn-type":[{"value":"0301-1623","type":"print"},{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,11,12]]}}}